Indaptus Therapeutics, Inc.
INDP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001857044
No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.15M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Indaptus Therapeutics, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Q1 2026 | Change |
|---|---|---|---|
| Holders | 4 | 6 | +2 |
| Shares | 32.2K | 70.6K | +38.4K (+119.4%) |
| Value | $93.7K | $128.5K | +$34.9K (+37.2%) |
New holders (4)
Institutions that held Indaptus Therapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 39,018 | $71.0K | 0.00% |
| Geode Capital Management, LLC | 27,007 | $49.2K | 0.00% |
| Morgan Stanley | 2,697 | $4.91K | 0.00% |
| CWM, LLC | 2 | $4 | 0.00% |
Sold out (2)
Institutions that held Indaptus Therapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| UBS Group AG | 29,002 | $84.4K |
| Bank of America Corp | 25 | $73 |